Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ADCT
ADC Therapeutics SA
stock NYSE

At Close
Jul 28, 2026 3:59:50 PM EDT
1.11USD-2.632%(-0.03)747,747
0.9600Bid   1.46Ask   0.50Spread
Pre-market
Jul 27, 2026 8:36:30 AM EDT
1.15USD0.000%(0.00)0
After-hours
Jul 28, 2026 4:10:30 PM EDT
1.11USD0.000%(0.00)1
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
07:15AM EST  ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022   Business Wire
Jan 18, 2022
07:05AM EST  ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan   Benzinga
05:14AM EST  ADC Therapeutics Unveils Exclusive License With Mitsubishi Tanabe Pharma To Develop ZYNLONTA In Japan   RTTNews
05:06AM EST  ADC Therapeutics Announced Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA in Japan; ADC Therapeutics to Receive $30M Upfront Payment Plus up to $205M in Milestones Plus Double-digit Royalties Based on Net Sales in Japan   Benzinga
05:00AM EST  ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA(r) (loncastuximab tesirine-lpyl) in Japan   Business Wire
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Nov 9, 2021
12:02PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021   Benzinga
11:45AM EST  Wolfe Research Initiates Coverage On ADC Therapeutics with Outperform Rating, Announces Price Target of $44   Benzinga
07:15AM EST  ADC Therapeutics to Participate in the Jefferies London Healthcare Conference   Business Wire
Nov 4, 2021
09:25AM EDT  ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting   Business Wire
Nov 3, 2021
09:20AM EDT  RBC Capital Maintains Outperform on ADC Therapeutics, Raises Price Target to $34   Benzinga
Nov 2, 2021
10:50AM EDT  ADC Therapeutics Q3 EPS $(0.59) Beats $(0.92) Estimate, Sales $13.15M Beat $7.39M Estimate   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
07:12AM EDT  ADC Therapeutics SA Q3 Loss/shr $0.93 Vs. Loss/shr $0.29 Last Year   RTTNews
07:00AM EDT  ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates   Business Wire
Oct 29, 2021
07:20AM EDT  ADC Therapeutics Announces Validation Of MAA By European Medicines Agency For ZYNLONTA For Relapsed Or Refractory DLBCL   RTTNews
07:16AM EDT  ADC Therapeutics reports Validation Of Its Marketing Authorization Application By European Medicines Agency For ZYNLONTA   Benzinga
07:15AM EDT  ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA(r)   Business Wire
Oct 27, 2021
07:15AM EDT  ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021   Business Wire
Sep 29, 2021
07:16AM EDT  Overland ADCT BioPharma Announces First Patient Dosed In China With ZYNLONTA In Pivotal Phase 2 Clinical Trial For Diffuse Large B-Cell Lymphoma   Benzinga
Sep 27, 2021
07:19AM EDT  ADC Therapeutics Doses First Patient In Phase 1 Clinical Trial Of ADCT-901 In Advanced Solid Tumors   RTTNews
Sep 23, 2021
07:15AM EDT  ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference   Business Wire
Sep 13, 2021
07:18AM EDT  ADC Therapeutics Gets Orphan Drug Designation In Europe For ZYNLONTA(r)   RTTNews
07:15AM EDT  ADC Therapeutics Receives Orphan Drug Designation In Europe For ZYNLONTA   Benzinga
Sep 9, 2021
07:15AM EDT  ADC Therapeutics to Participate in Morgan Stanley's 19th Annual Global Healthcare Conference   Business Wire
Sep 7, 2021
08:10AM EDT  Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $47   Benzinga
Sep 3, 2021
07:45AM EDT  ADC Therapeutics SA (ADCT) said Jay Feingold, Senior Vice President and Chief Medical Officer, will depart the company. Joseph Camardo will be appointed Senior Vice President and Chief Medical Officer. Camardo joined the company from Celgene Corporation, where he was most recently Senior Vice President of Celgene Global Health.   RTTNews
07:28AM EDT  ADC Therapeutics: SVP And Chief Medical Officer Jay Feingold To Depart To Pursue A New Opportunity   RTTNews
07:16AM EDT  ADC Therapeutics Announces Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer, Will Depart The Company; Co. Appoints Joseph Camardo MD, Senior Vice President and Chief Medical Officer   Benzinga
07:15AM EDT  ADC Therapeutics Announces Medical Leadership Transition   Business Wire
Aug 26, 2021
07:20AM EDT  ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325M; ADCT Will Sell Sells Capped Royalty Interest On ZYNLONTA And Cami For $225M Upon Closing With An Additional $100M In Potential Near-term Milestone Payments   Benzinga
07:19AM EDT  ADC Therapeutics Enters Royalty Purchase Agreement With HealthCare Royalty Partners For Up To $325 Mln   RTTNews
07:15AM EDT  ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million   Business Wire
Aug 9, 2021
10:24AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021   Benzinga
06:16AM EDT  RBC Capital Initiates Coverage On ADC Therapeutics with Outperform Rating, Announces Price Target of $33   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
07:28AM EDT  ADC Therapeutics Q2 Adj. EPS $(0.70) Beats $(0.82) Estimate, Sales $3.76M Beat $2.37M Estimate   Benzinga
07:18AM EDT  ADC Therapeutics Q2 Net Loss $72.6 Mln Or $0.95/shr Vs. Loss $126.6 Mln Or $2.01/shr Prior Year   RTTNews
07:00AM EDT  ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates   Business Wire
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 28, 2021
04:56PM EDT  ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021   Business Wire
Jul 16, 2021
08:03AM EDT  Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $51   Benzinga
Jun 22, 2021
10:05AM EDT  ADC Announces Interim Results From Pivotal Phase 2 Trial Of Camidanlumab Tesirine Presented   RTTNews
09:56AM EDT  ADC Therapeutics Highlights Interim Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine Presented At 16th Annual International Conference On Malignant Lymphoma   Benzinga
09:55AM EDT  ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma   Business Wire
Jun 18, 2021
07:27AM EDT  ADC Therapeutics Presents Updated ZYNLONTA Clinical Data At Annual International Conference On Malignant Lymphoma   RTTNews
07:16AM EDT  ADC Therapeutics Highlights Presentation Of Updated ZYNLONTA Clinical Data At 16th Annual International Conference On Malignant Lymphoma   Benzinga
07:15AM EDT  ADC Therapeutics Presents Updated ZYNLONTA(tm) (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma   Business Wire
Jun 15, 2021
01:03PM EDT  Expert Ratings for ADC Therapeutics   Benzinga
10:24AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021   Benzinga
09:16AM EDT  Cantor Fitzgerald Initiates Coverage On ADC Therapeutics with Overweight Rating, Announces Price Target of $46   Benzinga
Jun 11, 2021
07:19AM EDT  ADC Therapeutics Shareholders Approve All Resolutions At Annual General Meeting   RTTNews
07:15AM EDT  ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting   Business Wire
Jun 9, 2021
07:15AM EDT  ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma   Business Wire
Jun 4, 2021
01:53PM EDT  ADC Therapeutics Presents Updated Clinical Data At 2021 ASCO Meeting   Benzinga
01:52PM EDT  ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting   Business Wire
May 27, 2021
07:15AM EDT  ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference   Business Wire
May 26, 2021
07:20AM EDT  ADC Therapeutics Highlights Online Publication Of Camidanlumab Tesirine Phase 1 Results In The Lancet Haematology   Benzinga
07:15AM EDT  ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology   Business Wire
May 25, 2021
08:05AM EDT  Avid Bioservices to Serve as Commercial Manufacturer for ADC   GlobeNewswire Inc
May 19, 2021
06:15PM EDT  ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting   Business Wire
May 17, 2021
07:21AM EDT  ADC Therapeutics Announces Receipt Of $50M Second Tranche Of Convertible Credit Facility With Deerfield   Benzinga
07:15AM EDT  ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield   Business Wire
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
06:28AM EDT  HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $55   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
07:20AM EDT  ADC Therapeutics Announces Online Publication Of LOTIS-2 Results In The Lancet Oncology   RTTNews
07:16AM EDT  ADC Therapeutics Highlights Online Publication Of LOTIS-2 Results In The Lancet Oncology   Benzinga
07:15AM EDT  ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology   Business Wire
May 10, 2021
07:35AM EDT  Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $53   Benzinga
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:40AM EDT  ADC Therapeutics SA (ADCT) reported net loss of 51.5 million KUSD (Kowala), or $0.67 per share in the first quarter compared with net loss of 43.5 million KUSD or $0.85 per share, for the same quarter a year ago.   RTTNews
07:23AM EDT  ADC Therapeutics Q1 2021 EPS $(0.67) Beats $(0.90) Est   Benzinga
07:09AM EDT  ADC Therapeutics Q1 Loss Per Share $0.67 Vs Loss Per Share $0.85 Year Ago   RTTNews
07:00AM EDT  ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates   Business Wire
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
May 5, 2021
07:14PM EDT  ADC Therapeutics' ZYNLONTA(tm) (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network(r) Clinical Practice Guidelines in Oncology for B-cell Lymphomas   Business Wire
May 4, 2021
07:15AM EDT  ADC Therapeutics to Participate in May Investor Conferences   Business Wire
Apr 29, 2021
07:15AM EDT  ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021   Business Wire
Apr 26, 2021
06:33AM EDT  HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Raises Price Target to $57   Benzinga
06:12AM EDT  ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment   Benzinga
Apr 23, 2021
02:39PM EDT  ADC Therapeutics Announces FDA Approval Of ZYNLONTA In Relapsed or Refractory Diffuse Large B-Cell Lymphoma   Benzinga
02:38PM EDT  ADC Therapeutics Announces FDA Approval of ZYNLONTA(tm) (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma   Business Wire
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 6, 2021
07:08AM EDT  Overland ADCT BioPharma Appoints Eric Koo CEO   RTTNews
07:04AM EDT  Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer   Benzinga
07:03AM EDT  Overland ADCT BioPharma Appoints Eric Koo As CEO   RTTNews
07:00AM EDT  Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer   Business Wire
Mar 23, 2021
07:47AM EDT  Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $55   Benzinga
Mar 19, 2021
06:57AM EDT  HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Raises Price Target to $48   Benzinga
Mar 18, 2021
08:29AM EDT  ADC Therapeutics SA (ADCT), a late clinical stage oncology-focused biotechnology company, on Thursday reported fourth-quarter net loss of $56 million or $0.73 per share, wider than net loss of $35.3 million or $0.69 per share in the prior-year quarter.   RTTNews
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
07:07AM EDT  ADC Therapeutics Q4 EPS $(0.82) Misses $(0.38) Estimate   Benzinga
07:07AM EDT  Earnings Scheduled For March 18, 2021   Benzinga
07:05AM EDT  ADC Therapeutics Q4 Loss/Shr $0.73 Vs Loss $0.69 Last Year   RTTNews
07:00AM EDT  ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates   Business Wire
Mar 11, 2021
07:15AM EST  ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021   Business Wire
Feb 25, 2021
07:15AM EST  ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference   Business Wire
Feb 5, 2021
07:15AM EST  ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day   Business Wire
Feb 4, 2021
07:35AM EST  ADC Therapeutics Completes Enrollment In Pivotal Phase 2 Clinical Trial Of Cami In R/r Hodgkin Lymphoma   RTTNews
07:17AM EST  ADC Therapeutics Completes Enrollment In Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine (Cami) In Relapsed Or Refractory Hodgkin Lymphoma   Benzinga
Jan 7, 2021
07:22AM EST  ADC Therapeutics Initiates Expanded Access Program For Loncastuximab Tesirine In The U.S. In DLBCL   RTTNews
07:20AM EST  ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.   Benzinga
Jan 4, 2021
07:15AM EST  ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event   Business Wire
Dec 16, 2020
12:03PM EST  Morgan Stanley Maintains Overweight on ADC Therapeutics, Raises Price Target to $56   Benzinga
Dec 15, 2020
09:51AM EST  New York-based cross-border advisory firm M.S.Q. Ventures said Tuesday that its client, ADC Therapeutics SA (ADCT), has reached an agreement to jointly form a new company, Overland ADCT BioPharma (CY) Limited with Overland Pharmaceuticals, a biopharmaceutical company backed by Hillhouse Capital.   RTTNews
09:15AM EST  ADC Therapeutics And Overland Pharma Form JV To Expand ADC Drugs Development And commercialization iI Greater China And Singapore   Benzinga
09:09AM EST  ADC And Overland Pharma Form JV To Expand ADC Drugs Development And Commercialization In China And Singapore   RTTNews
09:04AM EST  Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures   PR Newswire
Dec 14, 2020
07:03AM EST  ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore   Benzinga
Dec 7, 2020
07:09AM EST  ADC Therapeutics: Encouraging Data Presented At 2020 ASH Meeting Reinforce Significant Progress Made With PBD-based ADCs   RTTNews
07:08AM EST  ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting   Benzinga
Dec 6, 2020
08:41AM EST  Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace   Benzinga
Dec 3, 2020
09:56AM EST  Benzinga's Top Upgrades, Downgrades For December 3, 2020   Benzinga
Nov 30, 2020
07:15AM EST  ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting   Business Wire
Nov 20, 2020
07:05AM EST  ADC:FDA Grants Priority Review For Lonca For Treatment Of Relapsed/Refractory Diffuse Large B-cell Lymphoma   RTTNews
07:02AM EST  ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma   Benzinga
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
07:24AM EST  ADC Therapeutics SA (ADCT) a clinical-stage oncology-focused biotechnology company, reported Thursday that its third-quarter net loss narrowed to $20.33 million or $0.29 per share, from net loss of $31.34 million or $0.62 per share for the same quarter in 2019.   RTTNews
07:10AM EST  ADC Therapeutics Q3 EPS $(0.29) Beats $(0.81) Estimate   Benzinga
07:05AM EST  ADC Therapeutics Q3 Loss Per Share $0.29; Adj Loss Per Share $0.58   RTTNews
07:00AM EST  ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights   Business Wire
04:18AM EST  Earnings Scheduled For November 12, 2020   Benzinga
Nov 10, 2020
07:15AM EST  ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference   Business Wire
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
07:15AM EST  ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020   Business Wire
Nov 4, 2020
11:01AM EST  ADC Therapeutics Announces Eight Presentations On Data From Its Next-Generation Antibody Drug Conjugates At The 62nd American Society Of Hematology Annual Meeting   Benzinga
Nov 3, 2020
07:21AM EST  ADC Therapeutics Announces First Patient Dosed With Camidanlumab Tesirine In Combination With Pembrolizumab In Ongoing Phase 1b Clinical Trial In Selected Solid Tumors   Benzinga
07:20AM EST  ADC Therapeutics Announces First Patient Dosed With Camidanlumab Tesirine With Pembrolizumab In Phase 1b Trial   RTTNews
07:15AM EST  ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors   Business Wire
Oct 30, 2020
07:23AM EDT  Genmab And ADC Therapeutics Announce Amended Agreement For Camidanlumab Tesirine   RTTNews
07:16AM EDT  Genmab, ADC Thearpeutics Report Execution Of Amended Deal For ADC To Continue Development, Commercialization Of Camidanlumab Tesirine For TAC Antibody Targeting   Benzinga
07:15AM EDT  Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)   Business Wire
Oct 29, 2020
09:32AM EDT  Benzinga's Top Upgrades, Downgrades For October 29, 2020   Benzinga
07:05AM EDT  HC Wainwright & Co. Initiates Coverage On ADC Therapeutics with Buy Rating, Announces Price Target of $47   Benzinga
Oct 22, 2020
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
Oct 13, 2020
08:13AM EDT  Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $52   Benzinga
Oct 9, 2020
04:18PM EDT  ADC Therapeutics Announces That It Exercised A Full Underwriters' Option to Purchase Additional Common Shares   Benzinga
04:15PM EDT  ADC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Common Shares   Business Wire
Oct 2, 2020
07:01AM EDT  New Ventures Funds Rebrands as Scientia Ventures   PR Newswire
Sep 24, 2020
05:37AM EDT  ADC Therapeutics Priced Upsized 6M Share Public Offering of Common Stock @$34/Share   Benzinga
Sep 23, 2020
09:34PM EDT  ADC Therapeutics Announces Pricing Of Upsized Public Offering Of 6 Mln Shares At $34.00/shr   RTTNews
08:54PM EDT  ADC Therapeutics Announces Pricing of Public Offering   Business Wire
Sep 22, 2020
02:31PM EDT  Mid-Afternoon Market Update: Dow Rises 100 Points; AIM ImmunoTech Shares Climb   Benzinga
Sep 21, 2020
05:11PM EDT  ADC Therapeutics Reports Commencement Of 5.5M Share Common Stock Offering   Benzinga
05:10PM EDT  ADC Therapeutics Announces Proposed Public Offering   Business Wire
04:05PM EDT  ADC Therapeutics Reports Submission Of Biologics License Application For Loncastuximab Tesirine For Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma   Benzinga
04:05PM EDT  ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma   Business Wire
Sep 17, 2020
07:22AM EDT  ADC Therapeutics Presents Preliminary Findings From Phase 1b Clinical Trial Of Cami In Advanced Solid Tumors   RTTNews
07:18AM EDT  ADC Therapeutics Highlights Presentation Of Preliminary Findings From Phase 1b Clinical Trial Of Camidanlumab Tesirine In Advanced Solid Tumors At ESMO Virtual Congress 2020   Benzinga
07:15AM EDT  ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020   Business Wire
Sep 14, 2020
02:47PM EDT  ADC Therapeutics 13D Filing From HPWH TH AG Shows 12.1% Stake In Co.   Benzinga
Sep 10, 2020
07:39AM EDT  ADC Therapeutics Announces Publication Highlighting 'the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers'   Benzinga
Sep 4, 2020
09:30PM EDT  ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131   Business Wire
Aug 18, 2020
07:45AM EDT  ADC Therapeutics Q2 EPS $(2.01) Misses $(0.67) Estimate   Benzinga
07:20AM EDT  ADC Therapeutics Q2 Net Loss $126.6 Mln Or $2.01/Shr Vs Loss $23.3 Mln Or $0.49/Shr Last Year   RTTNews
07:15AM EDT  ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights   Business Wire
04:02AM EDT  Earnings Scheduled For August 18, 2020   Benzinga
Aug 12, 2020
04:15PM EDT  ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020   Business Wire
Jul 17, 2020
07:17AM EDT  ADC Therapeutics Announces First Patient Dosed In Pivotal Phase 2 Portion Of LOTIS 3 Clinical Trial Of Loncastuximab Tesirine (Lonca) In Combination With Ibrutinib   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC